Modality
Small Molecule
MOA
CAR-T BCMA
Target
TYK2
Pathway
Epigenetic
PV
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
Jan 2020
→ Sep 2027
Phase 2Current
NCT04722586
261 pts·PV
2025-10→2027-04·Terminated
NCT03086036
961 pts·PV
2020-01→2027-09·Active
1,222 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-04-081.0y awayPh2 Data· PV
2027-09-031.4y awayPh2 Data· PV
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Active
P2
Termina…
Catalysts
Ph2 Data
2027-04-08 · 1.0y away
PV
Ph2 Data
2027-09-03 · 1.4y away
PV
ActiveTerminated|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| COR-9566 | Corcept | Approved | TYK2 | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA | |
| Olpasotorasib | Structure Ther | Preclinical | C5 | |
| SND-9531 | Syndax | Phase 3 | TYK2 | |
| RAR-1117 | Ultragenyx | Phase 1/2 | TYK2 |